This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
FOXA3 · Western blot design guide
FOXA3 Western Blot Planning Guide
Plan a FOXA3 Western blot around the catalog-observed 37.1 kDa band, image-backed PB9805 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
FOXA3 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 37.1 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Adipose tissue | |
| Negative control | Lymph node |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 37.1 kDa |
| ⓘ | Localization | Nucleus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated FOXA3 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adipose tissue |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9805 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected FOXA3 Western Blot Band Size?
Use the product-observed 37.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 37.1 kDa | Matches the authoritative product WB observation. |
| 37.1 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected FOXA3 appearancePlan around 37.1 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 37.1 kDa; use this as the primary experimental expectation. |
| Calculated mass | 37.1 kDa from UniProt P55318; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9805. |
| Situation | Likely cause | Next action |
|---|---|---|
| 37.1 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing FOXA3 band
PB9805 · FOXA3
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for FOXA3 Western blot
🧪Use Adipose tissue as the first positive-control candidate and Lymph node as the HPA Not detected negative candidate.
Positive control: Adipose tissue (High)
Negative control: Lymph node (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for FOXA3
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bronchus | Reported tissue cells | High | Protein (HPA) | HPA → |
| Caudate | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebral cortex | Reported tissue cells | High | Protein (HPA) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Lymph node | Reported tissue cells | Not detected | Protein (HPA) | HPA → |
Section 3
Advanced FOXA3 Western Blot Tips
Deeper troubleshooting and optimisation questions for FOXA3, answered from its protein features.
Which band should guide the blot?
Use 37.1 kDa, the observation attached to the authoritative PB9805 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 37.1 kDa expectation.
Which positive control should I start with?
Start with Adipose tissue, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Lymph node as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for FOXA3 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9805 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
FOXA3 Western Blot Reagents
Human/Mouse/Rat-reactive FOXA3 Western blot reagents with authoritative product imagery.
Real WB data
Anti-FOXA3 Antibody Picoband®
Cat # PB9805
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P55318
- Human Protein Atlas — FOXA3
- PB9805 product record
- PMC10590975 — HOXC10 promotes esophageal squamous cell carcinoma progression by targeting FOXA3 and indicates poor survival outcome (Heliyon, 2023)
- PMC7957975 — Transcription factor FOXA3 promotes the development of Hepatoblastoma via regulating HNF1A, AFP, and ZFHX3 expression (Journal of clinical laboratory analysis, 2021)
- PMC10999823 — Hepatic FOXA3 overexpression prevents Western diet-induced obesity and MASH through TGR5 (Journal of lipid research, 2024)
